期刊
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
卷 95, 期 1, 页码 135-143出版社
FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2008.001628
关键词
CD20; monoclonal antibodies; lymphoma; immunotherapy
类别
资金
- MRC
- Leukaemia Research
- Medical Research Council [G0800457] Funding Source: researchfish
- MRC [G0800457] Funding Source: UKRI
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据